Estrella Immunopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 06/30/24 | FY 06/30/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $10.2M | — | $4.1M | $10.5M | — |
| Operating expenses | $13.1M | — | $7.3M | $11.1M | — |
| Operating income | -$13.1M | — | -$7.3M | -$11.1M | -$1.6M |
| Pretax income | -$13.1M | — | -$7.3M | -$11.1M | -$915,456 |
| Income tax expense | $838 | — | $1,625 | — | $80,648 |
| Net income | -$13.1M | — | -$7.3M | -$11.1M | -$996,104 |
| Balance Sheet | |||||
| Cash and equivalents | $1.4M | $916,916 | $4.2M | $2.5M | $40,802 |
| Current assets | $1.7M | $1.6M | $4.5M | $2.8M | $52,427 |
| Total assets | $3.2M | $3.1M | $4.5M | $3.0M | $9.7M |
| Current liabilities | $13.5M | $3.0M | $180,701 | $9.8M | $1.1M |
| Total liabilities | $13.5M | $3.0M | $180,701 | $9.8M | $2.7M |
| Stockholders' equity | -$10.4M | $143,731 | $4.3M | -$11.7M | -$2.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$1.8M | — | -$16.1M | -$1.3M | -$1.0M |
| Stock-based compensation | $618,974 | — | $1.2M | $409,595 | — |
| Share repurchases | $29,462 | — | — | — | — |
Shares outstanding 43.0M · Free float 5.5%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.